The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
Report for the Calendar Year or Quarter Ended: 06-30-2018
Check here if Amendment    Amendment Number:
This Amendment (Check only one.):    is a restatement.
   adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: Woodford Investment Management Ltd
Address: 9400 Garsington Road
Oxford, X0  OX4 2HN
Form 13F File Number: 028-16850

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name: Chris Martin
Title: Head of Compliance
Phone: 44-0-1865-809041
Signature, Place, and Date of Signing:
/s/ Chris Martin Oxford,  X0 08-07-2018
[Signature] [City, State] [Date]
With respect to Evofem Biosciences, Inc. ("Evofem"), the Reporting Manager, acting as agent for and on behalf of the funds it manages who own shares of Evofem common stock, par value $0.0001 per share ("Evofem Stock") (the "Funds"), has entered into a voting agreement with Evofem, obligating the Reporting Manager to cause each Fund to deliver to Evofem a duly executed irrevocable proxy. Each Fund, including LF Woodford Equity Income Fund and Woodford Patient Capital Trust, who are Other Included Managers whose holdings are separately included on the Information Table, has executed and delivered such proxy to Evofem. The proxy appoints any designee of Evofem as the sole and exclusive attorney and proxy of the Fund to represent the Fund and to vote at every meeting of the stockholders of Evofem (including any actions by written consent) with respect to all the shares of Evofem Stock owned by the Fund in excess of 19.5% of the then outstanding shares of Evofem Stock in the same proportion as the shares voted by all other stockholders (excluding the Fund) voting on or consenting to such matters. Accordingly, each Fund (as record holder of the shares) only has voting power with respect to the shares it beneficially owns up to and including that 19.5% threshold ("Threshold Shares"); the Reporting Manager shares voting power with respect to such Threshold Shares. Voting authority with respect to the Evofem Stock over which neither the Reporting Manager nor the Funds has voting power (because such 19.5% threshold has been exceeded) is reported as "none" in Column 8 of the Information Table. For purposes of this calculation, the total outstanding Evofem shares used was 26,263,340 shares of Evofem Stock outstanding, which is the sum of the 17,763,340 shares outstanding as of April 30, 2018, as reported in Evofem's Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2018, plus the 8,500,000 shares registered on Form S-1 and sold by Evofem in May 2018. Please refer to the Form of Voting Agreement, which is incorporated by reference to Exhibit 4.10 of Evofem's Registration Statement on Form S-4 (No. 333-221592) filed on November 15, 2017 and the Reporting Manager's Schedule 13G with respect to the Evofem Stock filed by the Reporting Manager on June 11, 2018, for more information. All American Depositary Shares of Autolus Therapeutics PLC reported in the Information Table are subject to a Lock-Up Agreement, dated as of February 9, 2018.
Report Type (Check only one.):
X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
   13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
   13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)
Form 13F Summary Page
Report Summary:
Number of Other Included Managers: 5
Form 13F Information Table Entry Total: 25
Form 13F Information Table Value Total: 824,679
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state “NONE” and omit the column headings and list entries.]
No. Form 13F File Number Name
1 028-18455 LF Woodford Equity Income Fund
2 028-18454 SJPUT UK High Income
3 028-18453 SJPUK Net Distribution Bond
4 028-18456 Woodford Patient Capital Trust
5 028-18750 SJPUK EX UK Equity